Page last updated: 2024-10-17

cytosine and Neoplasms

cytosine has been researched along with Neoplasms in 170 studies

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
" We have recently shown in in vitro studies that inflammation-mediated halogenated cytosine damage products can mimic 5-methylcytosine in directing enzymatic DNA methylation and in enhancing the binding of methyl-binding proteins whereas certain oxidative damage products inhibit both."8.84Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. ( Sowers, LC; Valinluck, V, 2007)
"During chronic inflammation, neutrophil-secreted hypochlorous acid can damage nearby cells inducing the genomic accumulation of 5-chlorocytosine (5ClC), a known inflammation biomarker."7.81Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer. ( Chang, SC; Delaney, JC; Essigmann, JM; Fedeles, BI; Freudenthal, BD; Li, D; Singh, V; Wilson, SH; Yau, E, 2015)
"The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer."7.77Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. ( Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH, 2011)
" We have recently shown in in vitro studies that inflammation-mediated halogenated cytosine damage products can mimic 5-methylcytosine in directing enzymatic DNA methylation and in enhancing the binding of methyl-binding proteins whereas certain oxidative damage products inhibit both."4.84Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. ( Sowers, LC; Valinluck, V, 2007)
" We have previously reported that the wild-type cytosine/cytosine genotype of a common Desmin synonymous single nucleotide polymorphism (C > T) (rs1058261) associated with cardiovascular diseases in a cohort of subjects from the Tampere adult population cardiovascular risk study."4.12The gene variant for desmin rs1058261 may protect against combined cancer and cardiovascular death, the Tampere adult population cardiovascular risk study. ( Kunnas, T; Nikkari, ST; Piesanen, J, 2022)
"During chronic inflammation, neutrophil-secreted hypochlorous acid can damage nearby cells inducing the genomic accumulation of 5-chlorocytosine (5ClC), a known inflammation biomarker."3.81Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer. ( Chang, SC; Delaney, JC; Essigmann, JM; Fedeles, BI; Freudenthal, BD; Li, D; Singh, V; Wilson, SH; Yau, E, 2015)
"The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer."3.77Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. ( Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH, 2011)
"To assess the feasibility of administering troxacitabine, an L-nucleoside analog that is not a substrate for deoxycytidine deaminase, in combination with cisplatin, to identify pharmacokinetic interactions, and to seek preliminary evidence of antitumor activity."2.74Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. ( Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2009)
"Patients with solid tumors received troxacitabine as a progressively longer infusion on days 1-4 of a 28-day cycle."2.73Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. ( Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Lee, CK; Ma, WW; Messersmith, WA, 2008)
"9 h after drug administration and the terminal elimination half-life was 1."2.72A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. ( Braich, TA; Burch, PA; Camoriano, JK; Delaunoit, T; Erlichman, C; Kaur, JS; Kobayash, T; Reid, JM; Rubin, J, 2006)
"Plasma samples from 111 cancer patients receiving troxacitabine (0."2.72Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. ( Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK, 2006)
" After treatment on the fifth day, terminal half-life values averaged 39 (63) hours, and Cl(s) was reduced by approximately 20%, averaging 127 (27) mL/min."2.70Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. ( Baker, SD; de Bono, JS; Goetz, A; Hammond, LA; Hidalgo, M; Jolivet, J; Patnaik, A; Rowinsky, EK; Simmons, C; Siu, L; Stephenson, J; Weiss, G, 2002)
"25 to 3g) and multiple-dose study with one-day dosing (1 or 2g, every one or two hours, three times a day), bropirimine treatment was well tolerated by the patients with cancer."2.68[Bropirimine (U-54461S) phase I clinical studies]. ( Furue, H, 1996)
"Cytosine methylation plays a major role in the regulation of sequential and tissue-specific expression of genes."2.58Morphology-oriented epigenetic research. ( Haraguchi, R; Kitazawa, R; Kitazawa, S, 2018)
"Both normal and cancerous cells, treated with drugs that block cytosine methylation of DNA, are preferentially killed by these drugs when they have p53 mutations and survive if they have a wild type protein."2.55The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA. ( Levine, AJ, 2017)
"Given variability related to ethnicity, cancer types and detection methods, additional well-designed studies with larger sample sizes are required to further confirm our findings."2.55Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis. ( Chen, Z; Guo, L; He, J; Li, Y; Luo, M; Shi, X, 2017)
"Causal treatment can be given for influenza, using a neuraminidase inhibitor, and respiratory syncytial virus, using ribavirin in addition to intravenous immunoglobulins."2.53Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. ( Berger, A; Christopeit, M; Hauf, E; Hentrich, M; Heussel, CP; Kalkreuth, J; Klein, M; Kochanek, M; Lehners, N; Mayer, K; Penack, O; Rieger, C; Schalk, E; Silling, G; Vehreschild, M; von Lilienfeld-Toal, M; Weber, T; Wolf, HH, 2016)
"The role of miRNAs in cancer through hypo- and hypermethylation has also been explored and discussed."2.52Hydroxymethylation and its potential implication in DNA repair system: A review and future perspectives. ( Sehgal, M; Shukla, A; Singh, TR, 2015)
"Understanding mechanisms driving cancer diversity is a critical step toward developing strategies to attenuate tumor evolution and adaptation."2.52APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. ( Harris, RS; McGranahan, N; Starrett, GJ; Swanton, C, 2015)
"Sapacitabine is an orally bioavailable nucleoside analog prodrug that is in clinical trials for hematologic malignancies and solid tumors."2.48Sapacitabine for cancer. ( Kantarjian, H; Liu, X; Plunkett, W, 2012)
"The use of anti-HIV drugs as cancer treatments is not new."2.45Anti-HIV drugs for cancer therapeutics: back to the future? ( Chow, WA; Guan, M; Jiang, C, 2009)
"Cytosine methylation is a common form of post-replicative DNA modification seen in both bacteria and eukaryotes."2.43Cytosine methylation and DNA repair. ( Walsh, CP; Xu, GL, 2006)
"The unique properties of a cancer cell are acquired through a stepwise accumulation of heritable changes in the information content of proto-oncogenes and tumor suppressor genes."2.41DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. ( Guldberg, P; Worm, J, 2002)
"(1986) Cancer Res."2.40Mutagenic and epigenetic effects of DNA methylation. ( Gonzalgo, ML; Jones, PA, 1997)
"The focus on genetic alterations in cancer research has perhaps led to an underestimation of the contribution by epigenetics."2.40Oncogenic mechanisms mediated by DNA methylation. ( Laird, PW, 1997)
"Cytosine methylation is an important mechanism of gene regulation in mammals."2.39Experimental manipulation of genomic methylation. ( Jackson-Grusby, L; Jaenisch, R, 1996)
"The causes of much of human cancer remain obscure."2.39Mechanisms of spontaneous human cancers. ( Venitt, S, 1996)
"Mutations in lung cancer are therefore caused by a different mechanism than colorectal cancer and this presumably requires the direct interaction of carcinogens with DNA."2.385-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene. ( Coetzee, GA; Jones, PA; Olumi, AF; Rideout, WM; Spruck, CH, 1991)
"Additionally, DNMT2/TRDMT1 cancer mutant activity was collectively mediated by five enzymatic characteristics, which might impact gene expressions."1.91Determinants of DNMT2/TRDMT1 preference for substrates tRNA and DNA during the evolution. ( Cai, C; Chen, J; Chen, Y; Cheng, H; Li, H; Ma, Y; Qin, M; Xu, D; Xue, P; Yang, Y; Zhu, D, 2023)
"Based on the B16 cancer model, a cocktail regimen was developed that combined BPSi-based PTT with doxorubicin (DOX) and cytosine-phosphate-guanosine (CpG)."1.72Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy. ( Cerullo, V; Fan, L; Feola, S; Lehto, VP; Pang, C; Qian, J; Song, C; Xu, W; Yu, H, 2022)
" NV not only showed good tumor preventive effect, but also could successfully inhibited tumor development and metastasis when combined with anti-PD-L1, and induced long-term immune memory effect."1.72A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy. ( Chen, J; Chen, X; Feng, Y; Hao, K; Li, H; Li, Z; Lin, L; Meng, M; Tang, Z; Tian, H; Xu, C; Zhang, S, 2022)
" Because activated natural killer T (NKT) cells can cooperate with pattern-recognition via TLRs to improve adaptive immune responses, we assessed the impact of combining a repeated dosing regimen of intratumoural CpG with a single intratumoural dose of the NKT cell agonist α-galactosylceramide (α-GalCer)."1.72Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. ( Anderson, RJ; Burn, OK; Chen, CJ; Compton, BJ; Dasyam, N; Dundar, PR; Ferrer-Font, L; Godfrey, DI; Hermans, IF; Mattarollo, SR; Mayer, JU; Painter, GF; Prasit, KK; Ritchie, DS; Schmidt, AJ, 2022)
"The mutations found in murine tumors are similar to those found in human skin cancers, and PMA promotes proliferation of human skin cells."1.51A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils. ( Bhagwat, AS; Perera, MLW; Senevirathne, V; Siriwardena, SU; Stewart, J, 2019)
"Alternatively, the cancer cell line HCT116 preserves global epigenetic heterogeneity independently of cell-cycle arrest."1.48Global delay in nascent strand DNA methylation. ( Akopian, V; Charlton, J; Clement, K; Downing, TL; Gnirke, A; Gu, H; Kiskinis, E; Klages, S; Meissner, A; Pop, R; Santos, DP; Smith, ZD; Timmermann, B; Tsankov, AM; Ziller, MJ, 2018)
"Specifically, we discovered that lung cancer leads to a progressive global loss of 5hmC in cfDNA, whereas hepatocellular carcinoma and pancreatic cancer lead to disease-specific changes in the cell-free hydroxymethylome."1.465-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. ( Chen, Y; Chua, MS; Diao, J; Dong, B; Hu, J; Jeffrey, SS; Li, W; Liu, B; Ma, L; Quake, SR; So, S; Song, CX; Tian, Z; Wei, Y; Wheeler, A; Xie, D; Xiong, J; Yin, S; Zhang, W; Zhang, Y; Zhou, Z, 2017)
"We reviewed data of 4 cancer patients with resistant CMV or herpes simplex virus (HSV) infections and were treated with brincidofovir under emergency IND application."1.43Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. ( Ariza-Heredia, EJ; Chemaly, RF; El Chaer, F; El-Haddad, D; Gulbis, AM; Mulanovich, VE; Shah, DP; Shpall, EJ; Vanichanan, J, 2016)
"By analyzing genomic and exomic cancer databases, we show that >33% of dispersed APOBEC-induced mutations occur on the lagging strand during DNA replication, thus unraveling the major source of ssDNA targeted by APOBEC in cancer."1.43APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. ( Antonarakis, SE; Bazykin, GA; Nikolaev, SI; Popadin, KY; Seplyarskiy, VB; Soldatov, RA, 2016)
"Notably, by screening cancer cell lines for growth defects after exposure to 5hmdC, we unexpectedly identify a subset of cell lines in which 5hmdC or 5fdC administration leads to cell lethality."1.42CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. ( Berridge, G; Goldin, R; Kessler, BM; Kriaucionis, S; Pugh, KM; Thézénas, ML; Zauri, M, 2015)
"This cleansing function is required for cancer cell survival and to modulate Escherichia coli antibiotic sensitivity in a DNA polymerase (pol)-dependent manner."1.42Uncovering the polymerase-induced cytotoxicity of an oxidized nucleotide. ( Beard, WA; Freudenthal, BD; Kim, T; Perera, L; Schlick, T; Shock, DD; Wilson, SH, 2015)
"Gemcitabine is a nucleoside analog with many faces, which shows a remarkable activity in a variety of cancers, most likely because it has a unique metabolism, a so-called self-potentiation."1.38Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine. ( Diaz, I; Muggia, F; Peters, GJ, 2012)
"In squamous cell lung cancers, levels of 5hmdC were depleted substantially with up to 5-fold reduction compared with normal lung tissue."1.375-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. ( Jiang, Y; Jin, SG; Krex, D; Lu, Q; Pfeifer, GP; Qiu, R; Rauch, TA; Schackert, G; Wang, Y, 2011)
"One possible mechanism of the cancer caused by CpG methylation is the gene repression, which is a binding-inhibition of the sequence-specific transcription factors bound to specific DNA-binding sites."1.37Effect of CpG methylation on DNA binding protein: molecular dynamics simulations of the homeodomain PITX2 bound to the methylated DNA. ( Sun, CK; Wang, HB; Yang, SY; Yang, XL; Yao, LF, 2011)
"Epigenetic anti-cancer drugs with demethylating effects have shown to alter genome organization in mammalian cell nuclei."1.36Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells. ( Farkas, DL; Gertych, A; Tajbakhsh, J, 2010)
"With regard to cancer treatment, replication competent oncolytic adenoviruses have been safe in humans, although their efficacy has been variable."1.36Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. ( Bauerschmitz, GJ; Cerullo, V; Diaconu, I; Escutenaire, S; Hemminki, A; Hernandez-Alcoceba, R; Kanerva, A; Pesonen, S, 2010)
"With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level."1.33Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005)
"Human cancer cell lines are commonly used in basic cancer research to understand the behavior of primary tumors."1.32A systematic profile of DNA methylation in human cancer cell lines. ( Avila, S; Esteller, M; Fraga, MF; Guo, M; Herman, JG; Paz, MF; Pollan, M, 2003)
"Relative risks (RRs) of cancer and 95% confidence intervals (CIs) were calculated by Cox proportional hazards regression analysis."1.32Integrin beta3 Leu33Pro homozygosity and risk of cancer. ( Bojesen, SE; Nordestgaard, BG; Tybjaerg-Hansen, A, 2003)
"Second, tumors occurring in homozygous carriers of the methionine synthase 2756G allele show a lower number of hypermethylated CpG islands of tumor suppressor genes (P = 0."1.31Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. ( Avila, S; Capella, G; Esteller, M; Fraga, MF; Herman, JG; Paz, MF; Peinado, MA; Pollan, M; Sanchez-Cespedes, M, 2002)
"The major mutational hot spots in human cancers occur at CpG sequences in the p53 gene."1.30Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. ( Chen, JX; Tang, MS; West, M; Zheng, Y, 1998)
"In many cancers, the most frequent class of mutations is C to T changes within CG dinucleotides of the tumor suppressor gene p53."1.29A cytosine methyltransferase converts 5-methylcytosine in DNA to thymine. ( Bhagwat, AS; Yebra, MJ, 1995)
"Most of the metastatic neoplasms had significantly lower genomic m5C contents than did most of the benign neoplasms or normal tissues."1.27The 5-methylcytosine content of DNA from human tumors. ( Ehrlich, M; Gama-Sosa, MA; Gehrke, CW; Kuo, KC; Oxenhandler, R; Slagel, VA; Trewyn, RW, 1983)
"The results show that while tumors of the same histological type had similar 5-methylcytosine values, discrepancies existed between values obtained for fresh tumors and their corresponding cell lines."1.27Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. ( Bogenmann, E; Flatau, E; Jones, PA, 1983)
" Pharmacologic studies demonstrated a significant decrease in the bioavailability of the drug as it was administered in this study."1.27Phase I study of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer, in cancer patients. ( Fitzpatrick, FA; Gutknecht, GD; Hersh, EM; Reele, SB; Rios, A; Stringfellow, DA, 1986)

Research

Studies (170)

TimeframeStudies, this research(%)All Research%
pre-199027 (15.88)18.7374
1990's27 (15.88)18.2507
2000's34 (20.00)29.6817
2010's70 (41.18)24.3611
2020's12 (7.06)2.80

Authors

AuthorsStudies
Manayia, AH1
Ilhami, FB1
Lee, AW1
Cheng, CC1
Song, N1
Sim, JA1
Dong, Q1
Zheng, Y2
Hou, L1
Li, Z2
Hsu, CW1
Pan, H1
Mulder, H1
Easton, J1
Walker, E1
Neale, G1
Wilson, CL1
Ness, KK1
Krull, KR1
Srivastava, DK1
Yasui, Y1
Zhang, J1
Hudson, MM1
Robison, LL1
Huang, IC1
Wang, Z3
Besaratinia, A1
Caceres, A1
Tommasi, S1
Prasit, KK1
Ferrer-Font, L1
Burn, OK1
Anderson, RJ1
Compton, BJ1
Schmidt, AJ1
Mayer, JU1
Chen, CJ1
Dasyam, N1
Ritchie, DS1
Godfrey, DI1
Mattarollo, SR1
Dundar, PR1
Painter, GF1
Hermans, IF1
Yu, J1
Chai, X1
Pang, J1
Zhao, H1
Xie, T1
Xu, L1
Sheng, R1
Li, D2
Zeng, S1
Hou, T1
Kang, Y1
Xu, W1
Pang, C1
Song, C1
Qian, J1
Feola, S1
Cerullo, V2
Fan, L1
Yu, H1
Lehto, VP1
Zhang, S1
Feng, Y1
Meng, M1
Li, H2
Lin, L1
Xu, C1
Chen, J2
Hao, K1
Tang, Z1
Tian, H1
Chen, X1
Piesanen, J1
Kunnas, T1
Nikkari, ST1
An, J1
Ko, M1
Zhu, D1
Yang, Y1
Ma, Y1
Chen, Y3
Xue, P1
Qin, M1
Xu, D1
Cai, C1
Cheng, H1
Chen, H1
Yang, H2
Zhu, X1
Yadav, T1
Ouyang, J1
Truesdell, SS1
Tan, J1
Wang, Y2
Duan, M1
Wei, L1
Zou, L1
Levine, AS1
Vasudevan, S1
Lan, L1
Sanchez-Martin, V1
Lopez-Pujante, C1
Soriano-Rodriguez, M1
Garcia-Salcedo, JA1
Youn, HD1
López, V1
Fernández, AF1
Fraga, MF3
Coulter, JB1
Lopez-Bertoni, H1
Kuhns, KJ1
Lee, RS1
Laterra, J1
Bressler, JP1
Song, CX2
Yin, S1
Ma, L1
Wheeler, A1
Zhang, Y4
Liu, B1
Xiong, J1
Zhang, W1
Hu, J1
Zhou, Z1
Dong, B1
Tian, Z1
Jeffrey, SS1
Chua, MS1
So, S1
Li, W1
Wei, Y1
Diao, J1
Xie, D1
Quake, SR1
Liu, Z1
Dong, K2
Liu, C2
Ran, X1
Pu, F1
Ju, E1
Ren, J1
Qu, X1
Charlton, J1
Downing, TL1
Smith, ZD1
Gu, H1
Clement, K1
Pop, R1
Akopian, V1
Klages, S1
Santos, DP1
Tsankov, AM1
Timmermann, B1
Ziller, MJ1
Kiskinis, E1
Gnirke, A1
Meissner, A1
Kitazawa, S1
Haraguchi, R1
Kitazawa, R1
Siriwardena, SU1
Perera, MLW1
Senevirathne, V1
Stewart, J1
Bhagwat, AS2
Bunkar, N1
Shandilya, R1
Bhargava, A1
Samarth, RM1
Tiwari, R1
Mishra, DK1
Srivastava, RK1
Sharma, RS1
Lohiya, NK1
Mishra, PK1
Matsumoto, T1
Shirakawa, K1
Yokoyama, M1
Fukuda, H1
Sarca, AD1
Koyabu, S1
Yamazaki, H1
Kazuma, Y1
Matsui, H1
Maruyama, W1
Nagata, K1
Tanabe, F1
Kobayashi, M1
Shindo, K1
Morishita, R1
Sato, H1
Takaori-Kondo, A1
Haffner, MC1
Pellakuru, LG1
Ghosh, S1
Lotan, TL1
Nelson, WG1
De Marzo, AM1
Yegnasubramanian, S1
Głowacki, S1
Błasiak, J1
Cadet, J1
Wagner, JR1
Kohli, RM1
Ye, C1
Li, L1
Laird, A1
Thomson, JP1
Harrison, DJ1
Meehan, RR1
Johansson, C1
Tumber, A1
Che, K1
Cain, P1
Nowak, R1
Gileadi, C1
Oppermann, U1
Wu, YC1
Ling, ZQ2
Pfeifer, GP4
Xiong, W1
Hahn, MA1
Jin, SG2
Delatte, B1
Deplus, R1
Fuks, F1
Shen, L1
He, C1
Boele, J1
Persson, H1
Shin, JW1
Ishizu, Y1
Newie, IS1
Søkilde, R1
Hawkins, SM1
Coarfa, C1
Ikeda, K1
Takayama, K1
Horie-Inoue, K1
Ando, Y1
Burroughs, AM1
Sasaki, C1
Suzuki, C1
Sakai, M1
Aoki, S1
Ogawa, A1
Hasegawa, A1
Lizio, M1
Kaida, K1
Teusink, B1
Carninci, P1
Suzuki, H1
Inoue, S1
Gunaratne, PH1
Rovira, C1
Hayashizaki, Y1
de Hoon, MJ1
Arab, K1
Park, YJ1
Lindroth, AM1
Schäfer, A1
Oakes, C1
Weichenhan, D1
Lukanova, A1
Lundin, E1
Risch, A1
Meister, M1
Dienemann, H1
Dyckhoff, G1
Herold-Mende, C1
Grummt, I1
Niehrs, C1
Plass, C2
Huang, Y1
Rao, A1
Lian, CG1
Xu, S1
Guo, W1
Yan, J1
Frank, MY1
Liu, R1
Murphy, GF1
Chen, T1
Ficz, G1
Gribben, JG1
Freudenthal, BD2
Beard, WA1
Perera, L1
Shock, DD1
Kim, T1
Schlick, T1
Wilson, SH2
Rodger, EJ1
Chatterjee, A1
Morison, IM1
Chowdhury, B1
Cho, IH1
Hahn, N1
Irudayaraj, J1
Andrei, G1
Topalis, D1
De Schutter, T1
Snoeck, R1
Kroeze, LI1
van der Reijden, BA1
Jansen, JH1
Shukla, A1
Sehgal, M1
Singh, TR1
Vasanthakumar, A1
Godley, LA1
Tu, J1
Liao, J1
Luk, AC1
Tang, NL1
Chan, WY1
Lee, TL1
Swanton, C1
McGranahan, N1
Starrett, GJ1
Harris, RS1
Zauri, M1
Berridge, G1
Thézénas, ML1
Pugh, KM1
Goldin, R1
Kessler, BM1
Kriaucionis, S1
Sivanand, S1
Wellen, KE1
Fedeles, BI1
Yau, E1
Singh, V1
Chang, SC1
Delaney, JC1
Essigmann, JM1
Neupane, M1
Clark, AP1
Landini, S1
Birkbak, NJ1
Eklund, AC1
Lim, E1
Culhane, AC1
Barry, WT1
Schumacher, SE1
Beroukhim, R1
Szallasi, Z1
Vidal, M1
Hill, DE1
Silver, DP1
Popis, MC1
Blanco, S1
Frye, M1
Seplyarskiy, VB1
Soldatov, RA1
Popadin, KY1
Antonarakis, SE1
Bazykin, GA1
Nikolaev, SI1
Liu, FT1
Zhu, PQ1
Ou, YX1
Liu, WW1
Xia, GF1
Luo, HL1
Pataillot-Meakin, T1
Pillay, N1
Beck, S2
Rasmussen, KD1
Helin, K1
El-Haddad, D1
El Chaer, F1
Vanichanan, J1
Shah, DP1
Ariza-Heredia, EJ1
Mulanovich, VE1
Gulbis, AM1
Shpall, EJ1
Chemaly, RF1
von Lilienfeld-Toal, M1
Berger, A1
Christopeit, M1
Hentrich, M1
Heussel, CP1
Kalkreuth, J1
Klein, M1
Kochanek, M1
Penack, O1
Hauf, E1
Rieger, C1
Silling, G1
Vehreschild, M1
Weber, T1
Wolf, HH1
Lehners, N1
Schalk, E1
Mayer, K1
Chen, Z1
Shi, X1
Guo, L1
Li, Y1
Luo, M1
He, J1
Levine, AJ1
Chow, WA1
Jiang, C1
Guan, M1
Lao, VV1
Herring, JL1
Kim, CH1
Darwanto, A1
Soto, U1
Sowers, LC2
Lin, CC2
Beeram, M2
Rowinsky, EK3
Takimoto, CH2
Ng, CM2
Geyer, CE1
Denis, LJ1
De Bono, JS2
Hao, D1
Tolcher, AW1
Rha, SY1
Jolivet, J6
Patnaik, A3
Suter, JD1
Howard, DJ1
Shi, H1
Caldwell, CW1
Fan, X1
Diaconu, I1
Escutenaire, S1
Kanerva, A1
Bauerschmitz, GJ1
Hernandez-Alcoceba, R1
Pesonen, S1
Hemminki, A1
Olinski, R2
Jurgowiak, M2
Zaremba, T1
Gertych, A1
Farkas, DL1
Tajbakhsh, J1
Riahi, S1
Eynollahi, S1
Ganjali, MR1
Green, SR2
Choudhary, AK1
Fleming, IN1
Su, Z1
Han, L1
Zhao, Z1
Boeva, V1
Zinovyev, A1
Bleakley, K1
Vert, JP1
Janoueix-Lerosey, I1
Delattre, O1
Barillot, E1
Lingaraju, GM1
Davis, CA1
Setser, JW1
Samson, LD1
Drennan, CL1
Mikulski, D1
Szeląg, M1
Molski, M1
Yang, SY1
Yang, XL1
Yao, LF1
Wang, HB1
Sun, CK1
Münzel, M1
Globisch, D1
Carell, T1
Tjon Pian Gi, RE1
Dietz, A1
Djukic, V1
Eckel, HE1
Friedrich, G1
Golusinski, W1
Hantzakos, A1
Lawson, G1
Remacle, M1
Rihkanen, H1
Dikkers, FG1
Jiang, Y1
Qiu, R1
Rauch, TA1
Schackert, G1
Krex, D1
Lu, Q1
Kudo, Y1
Tateishi, K1
Yamamoto, K1
Yamamoto, S1
Asaoka, Y1
Ijichi, H1
Nagae, G1
Yoshida, H1
Aburatani, H1
Koike, K1
Liu, X1
Kantarjian, H1
Plunkett, W1
Liu, Y1
Bai, F1
Zhang, JY1
Ma, SH1
Liu, J1
Xu, ZD1
Zhu, HG1
Ye, D1
Guan, KL1
Xiong, Y1
Muggia, F1
Diaz, I1
Peters, GJ1
Tan, L1
Shi, YG1
Krečmerová, M1
Otmar, M1
Guz, J1
Kinney, SR1
Pradhan, S1
Paz, MF2
Avila, S2
Pollan, M2
Capella, G1
Peinado, MA1
Sanchez-Cespedes, M1
Herman, JG3
Esteller, M2
Piyathilake, CJ1
Johanning, GL1
Worm, J1
Guldberg, P1
Ecker, G1
Novik, KL1
Nimmrich, I1
Genc, B1
Maier, S1
Piepenbrock, C1
Olek, A1
Guo, M1
Bojesen, SE1
Tybjaerg-Hansen, A1
Nordestgaard, BG1
KAMMEN, HO1
HURLBERT, RB1
HAREL, J1
HAREL, L1
LACOUR, F1
BOER, A1
IMBENOTTE, J1
GREKH, IF2
TURBINA, IL2
KARLINSKAIA, RS2
AKSAMITNAIA, Ia1
EVANS, JS3
BOSTWICK, L2
MENGEL, GD3
MUSSER, EA1
RAPP, F1
MELNICK, JL1
KITAHARA, T1
RABOTTI, G1
MANOILOV, SE1
KITAVIN, GS1
COMAR, VE1
ORLOVA, EU1
CHU, MY1
FISCHER, GA1
OKAMURA, N1
BUSCH, H1
Matsuda, A1
Sasaki, T1
Gourdeau, H2
Leblond, L1
Hamelin, B1
Ouellet, F1
Boudreau, C1
Custeau, D1
Richard, A1
Gilbert, MJ1
Sandoval Guerrero, K1
Revilla Vázquez, A1
Segura-Pacheco, B1
Dueñas-Gonzalez, A1
Hoffman, RM2
Cieplik, J1
Inglis, AF1
Delaunoit, T1
Burch, PA1
Reid, JM1
Camoriano, JK1
Kobayash, T1
Braich, TA1
Kaur, JS1
Rubin, J1
Erlichman, C1
Walsh, CP2
Xu, GL1
Gekeler, V1
Gimmnich, P1
Hofmann, HP1
Grebe, C1
Römmele, M1
Leja, A1
Baudler, M1
Benimetskaya, L1
Gonser, B1
Pieles, U1
Maier, T1
Wagner, T1
Sanders, K1
Beck, JF1
Hanauer, G1
Stein, CA1
Asada, K1
Asada, R1
Yoshiji, H1
Fukui, H1
Floyd, RA1
Kotake, Y1
Lee, CK2
Li, J1
Giles, F1
Moore, MJ1
Hidalgo, M3
Capparelli, E1
Baker, SD4
Valinluck, V1
Serova, M1
Galmarini, CM1
Ghoul, A1
Benhadji, K1
Chiao, J1
Faivre, S1
Cvitkovic, E1
Le Tourneau, C1
Calvo, F1
Raymond, E1
Jimeno, A1
Messersmith, WA1
Ma, WW1
Laheru, D1
Donehower, RC1
Riggs, AD1
Jones, PA13
Gama-Sosa, MA1
Slagel, VA1
Trewyn, RW1
Oxenhandler, R1
Kuo, KC1
Gehrke, CW1
Ehrlich, M1
Nyce, J1
Weinhouse, S1
Magee, PN1
Diala, ES1
Cheah, MS1
Rowitch, D1
Flatau, E1
Bogenmann, E2
Wasternack, C1
Yebra, MJ1
Little, M1
Wainwright, B1
Merlo, A1
Mao, L1
Lee, DJ1
Gabrielson, E1
Burger, PC1
Baylin, SB1
Sidransky, D1
Holliday, R1
Grigg, GW1
Goodman, JI1
Counts, JL1
von Borstel, RC1
Hennig, UG1
Spruck, CH3
Rideout, WM3
Harris, CC1
Heby, O1
Venitt, S1
Bird, AP1
Furue, H1
Jackson-Grusby, L1
Jaenisch, R1
Gonzalgo, ML2
Wachsman, JT1
Zingg, JM1
Laird, PW1
Yoder, JA1
Bestor, TH2
Holmquist, GP1
Robertson, KD2
Denissenko, MF1
Chen, JX1
West, M1
Tang, MS1
Warnecke, PM1
Boos, G1
Stopper, H1
Santini, V1
Kantarjian, HM1
Issa, JP1
Costello, JF1
Watanabe, Y1
Fujiyama, A1
Ichiba, Y1
Hattori, M1
Yada, T1
Sakaki, Y1
Ikemura, T1
Stephenson, J1
Hammond, LA1
Weiss, G1
Goetz, A1
Siu, L2
Simmons, C1
Bélanger, K1
Moore, M1
Dionne, J1
Maclean, M1
Soulières, D1
Wainman, N1
Seymour, L1
Lakings, DB1
Waalkes, TP1
Mrochek, JE1
Sutow, WW1
Sullivan, MP1
Bingham, CA1
Shen, JC1
Tsai, YC1
Coetzee, GA1
Olumi, AF1
Rios, A1
Stringfellow, DA1
Fitzpatrick, FA1
Reele, SB1
Gutknecht, GD1
Hersh, EM1
Chandler, LA2
DeClerck, YA1
Mishra, PC1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer[NCT02363647]10 participants (Actual)Interventional2015-01-31Terminated (stopped due to No Current Funding)
Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia[NCT03339700]Phase 215 participants (Anticipated)Interventional2018-09-15Recruiting
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499]Phase 253 participants (Actual)Interventional2010-01-31Completed
Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial[NCT04482621]Phase 233 participants (Actual)Interventional2020-09-14Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

74 reviews available for cytosine and Neoplasms

ArticleYear
DNA Hydroxymethylation in Smoking-Associated Cancers.
    International journal of molecular sciences, 2022, Feb-28, Volume: 23, Issue:5

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; Epigenesis, Genetic; Mammals; Neoplasms; Proto

2022
Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation.
    International journal of molecular sciences, 2023, Jan-15, Volume: 24, Issue:2

    Topics: 5-Methylcytosine; Animals; Cell Differentiation; Cell Transformation, Neoplastic; Cytosine; Dioxygen

2023
An Updated Focus on Quadruplex Structures as Potential Therapeutic Targets in Cancer.
    International journal of molecular sciences, 2020, Nov-24, Volume: 21, Issue:23

    Topics: Cytosine; DNA; G-Quadruplexes; Gene Expression Regulation, Neoplastic; Guanine; Humans; Molecular Ta

2020
The role of 5-hydroxymethylcytosine in development, aging and age-related diseases.
    Ageing research reviews, 2017, Volume: 37

    Topics: 5-Methylcytosine; Aging; Animals; Cell Differentiation; Cytosine; DNA Methylation; Epigenesis, Genet

2017
Morphology-oriented epigenetic research.
    Histochemistry and cell biology, 2018, Volume: 150, Issue:1

    Topics: CpG Islands; Cytosine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Neoplasms; Prom

2018
Nano-engineered flavonoids for cancer protection.
    Frontiers in bioscience (Landmark edition), 2019, 03-01, Volume: 24, Issue:6

    Topics: Acetylation; Animals; Cell Line, Tumor; Cytosine; Dietary Supplements; DNA Methylation; Drug Deliver

2019
[Role of 5-hydroxymethylcytosine and TET proteins in epigenetic regulation of gene expression].
    Postepy biochemii, 2013, Volume: 59, Issue:1

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Hem

2013
TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine.
    Mutation research. Genetic toxicology and environmental mutagenesis, 2014, Volume: 764-765

    Topics: 5-Methylcytosine; Animals; Cytosine; Dioxygenases; DNA; DNA Methylation; DNA Repair; Humans; Models,

2014
TET enzymes, TDG and the dynamics of DNA demethylation.
    Nature, 2013, Oct-24, Volume: 502, Issue:7472

    Topics: 5-Methylcytosine; Animals; Blastocyst; Cellular Reprogramming; Cytosine; DNA Methylation; DNA Repair

2013
5-hydroxymethylcytosine: a new insight into epigenetics in cancer.
    Cancer biology & therapy, 2014, Volume: 15, Issue:1

    Topics: 5-Methylcytosine; Animals; Brain Neoplasms; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Pro

2014
5-hydroxymethylcytosine profiling as an indicator of cellular state.
    Epigenomics, 2013, Volume: 5, Issue:6

    Topics: 5-Methylcytosine; Animals; Biomarkers, Tumor; Cytosine; DNA Methylation; Epigenesis, Genetic; Gene E

2013
The roles of Jumonji-type oxygenases in human disease.
    Epigenomics, 2014, Volume: 6, Issue:1

    Topics: Cytosine; DNA Methylation; Epigenesis, Genetic; Humans; Inflammation; Jumonji Domain-Containing Hist

2014
The role of TET family proteins and 5-hydroxymethylcytosine in human tumors.
    Histology and histopathology, 2014, Volume: 29, Issue:8

    Topics: 5-Methylcytosine; Cell Transformation, Neoplastic; Cytosine; DNA Methylation; DNA-Binding Proteins;

2014
The role of 5-hydroxymethylcytosine in human cancer.
    Cell and tissue research, 2014, Volume: 356, Issue:3

    Topics: 5-Methylcytosine; Cytosine; DNA Methylation; DNA, Neoplasm; Humans; Neoplasms; Oxidation-Reduction

2014
Playing TETris with DNA modifications.
    The EMBO journal, 2014, Jun-02, Volume: 33, Issue:11

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Gen

2014
Mechanism and function of oxidative reversal of DNA and RNA methylation.
    Annual review of biochemistry, 2014, Volume: 83

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA; DNA Methylation; Escherichia coli; Gene Expression Regulat

2014
Connections between TET proteins and aberrant DNA modification in cancer.
    Trends in genetics : TIG, 2014, Volume: 30, Issue:10

    Topics: 5-Methylcytosine; Azacitidine; Cytosine; Decitabine; Dioxygenases; DNA Methylation; DNA Modification

2014
Loss of 5-hydroxymethylcytosine in cancer: cause or consequence?
    Genomics, 2014, Volume: 104, Issue:5

    Topics: 5-Methylcytosine; Animals; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; DNA, Neopl

2014
5-hydroxymethylcytosine: a potential therapeutic target in cancer.
    Epigenomics, 2014, Volume: 6, Issue:5

    Topics: 5-Methylcytosine; Animals; Antineoplastic Agents; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DN

2014
Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia.
    Antiviral research, 2015, Volume: 114

    Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Cell Proliferation; Cidofovir; C

2015
5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer.
    Biochimica et biophysica acta, 2015, Volume: 1855, Issue:2

    Topics: 5-Methylcytosine; Biomarkers, Tumor; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Proteins;

2015
Hydroxymethylation and its potential implication in DNA repair system: A review and future perspectives.
    Gene, 2015, Jun-15, Volume: 564, Issue:2

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA Repair; Humans; Mental Disorders; Neoplasms; Neurodegenerat

2015
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy.
    Cancer genetics, 2015, Volume: 208, Issue:5

    Topics: 5-Methylcytosine; Cytosine; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA

2015
MicroRNAs mediated targeting on the Yin-yang dynamics of DNA methylation in disease and development.
    The international journal of biochemistry & cell biology, 2015, Volume: 67

    Topics: Animals; Chromatin Assembly and Disassembly; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DNA Met

2015
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
    Cancer discovery, 2015, Volume: 5, Issue:7

    Topics: APOBEC Deaminases; Cytidine Deaminase; Cytosine; Cytosine Deaminase; Deamination; Evolution, Molecul

2015
Posttranscriptional methylation of transfer and ribosomal RNA in stress response pathways, cell differentiation, and cancer.
    Current opinion in oncology, 2016, Volume: 28, Issue:1

    Topics: Cell Differentiation; Cytidine; Cytosine; Humans; Methylation; Methyltransferases; Neoplasms; RNA Pr

2016
Positive association between IL-16 rs1131445 polymorphism and cancer risk: a meta-analysis.
    Minerva medica, 2016, Volume: 107, Issue:2

    Topics: Alleles; Asian People; Biomarkers, Tumor; Cytosine; Databases, Factual; Evidence-Based Medicine; Gen

2016
Role of TET enzymes in DNA methylation, development, and cancer.
    Genes & development, 2016, Apr-01, Volume: 30, Issue:7

    Topics: Animals; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Gene Ex

2016
Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 67

    Topics: Adenovirus Infections, Human; Antiviral Agents; Cidofovir; Community-Acquired Infections; Cytosine;

2016
Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis.
    Oncotarget, 2017, Jan-03, Volume: 8, Issue:1

    Topics: 5-Methylcytosine; Cytosine; DNA Methylation; Humans; Lymphatic Metastasis; Neoplasms; Prognosis

2017
The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Death; Cytosine; Decitabine; DNA Methyla

2017
Anti-HIV drugs for cancer therapeutics: back to the future?
    The Lancet. Oncology, 2009, Volume: 10, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cidofovir; Cytosine; HIV Protease Inhibitors

2009
Uracil in DNA--its biological significance.
    Mutation research, 2010, Volume: 705, Issue:3

    Topics: Animals; B-Lymphocytes; Cytosine; Cytosine Deaminase; DNA; Drosophila melanogaster; Escherichia coli

2010
5-Hydroxymethylcytosine, the sixth base of the genome.
    Angewandte Chemie (International ed. in English), 2011, Jul-11, Volume: 50, Issue:29

    Topics: 5-Methylcytosine; Animals; Bacteriophages; Cell Differentiation; Central Nervous System; Chromatogra

2011
Sapacitabine for cancer.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:4

    Topics: Animals; Arabinonucleosides; Cell Cycle; Clinical Trials as Topic; Cytosine; DNA Damage; Drug Evalua

2012
Tet family proteins and 5-hydroxymethylcytosine in development and disease.
    Development (Cambridge, England), 2012, Volume: 139, Issue:11

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA-Binding Proteins; Embryonic Development; E

2012
5-azacytosine compounds in medicinal chemistry: current stage and future perspectives.
    Future medicinal chemistry, 2012, Volume: 4, Issue:8

    Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Azacitidine; Cytosine; DNA Methylation; Drug Discov

2012
[Oxidation and deamination of nucleobases as an epigenetic tool].
    Postepy higieny i medycyny doswiadczalnej (Online), 2012, May-24, Volume: 66

    Topics: 5-Methylcytosine; Animals; Base Composition; Chromatin Assembly and Disassembly; Cytosine; Deaminati

2012
Ten eleven translocation enzymes and 5-hydroxymethylation in mammalian development and cancer.
    Advances in experimental medicine and biology, 2013, Volume: 754

    Topics: 5-Methylcytosine; Animals; Cell Differentiation; Cytosine; Dioxygenases; DNA Methylation; DNA-Bindin

2013
DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2002, Volume: 31, Issue:8

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Chromatin; CpG Islands; Cytosine; DNA Methylation; DNA Mod

2002
Epigenomics: genome-wide study of methylation phenomena.
    Current issues in molecular biology, 2002, Volume: 4, Issue:4

    Topics: Autoimmune Diseases; Chromosome Mapping; CpG Islands; Cytosine; DNA Methylation; DNA Modification Me

2002
Antitumor activity of sugar-modified cytosine nucleosides.
    Cancer science, 2004, Volume: 95, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Carbohydrates; Cytosine; Humans; Neoplasms; Pyrimidine Nuc

2004
[Troxacitabine].
    Bulletin du cancer, 2004, Volume: 91, Issue:3

    Topics: Acute Disease; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, P

2004
Pyrimidines as the cytostatic drugs.
    Acta poloniae pharmaceutica, 1992, Volume: 49, Issue:4

    Topics: Animals; Antineoplastic Agents; Cytosine; Drug Design; Folic Acid; Humans; Neoplasms; Pyrimidines

1992
Cytosine methylation and DNA repair.
    Current topics in microbiology and immunology, 2006, Volume: 301

    Topics: 5-Methylcytosine; Animals; Bacteria; CpG Islands; Cytosine; Dealkylation; Deamination; DNA Glycosyla

2006
Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers.
    Cancer research, 2007, Jun-15, Volume: 67, Issue:12

    Topics: Animals; Cell Transformation, Neoplastic; Cytosine; DNA Damage; DNA Methylation; Epigenesis, Genetic

2007
5-methylcytosine, gene regulation, and cancer.
    Advances in cancer research, 1983, Volume: 40

    Topics: 5-Methylcytosine; Animals; Azacitidine; Base Sequence; Carcinogens; Cell Transformation, Neoplastic;

1983
5-Methylcytosine depletion during tumour development: an extension of the miscoding concept.
    British journal of cancer, 1983, Volume: 48, Issue:4

    Topics: 5-Methylcytosine; Alkylation; Amino Acid Metabolism, Inborn Errors; Animals; Carcinogens; Cell Trans

1983
Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences.
    Pharmacology & therapeutics, 1980, Volume: 8, Issue:3

    Topics: Aminoisobutyric Acids; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Aza Compounds; Bar

1980
DNA methylation and mutation.
    Mutation research, 1993, Volume: 285, Issue:1

    Topics: 5-Methylcytosine; Animals; Base Composition; Cytosine; Dinucleoside Phosphates; DNA; DNA Repair; Hum

1993
Spontaneous mutations and fidelogens.
    Basic life sciences, 1993, Volume: 61

    Topics: 5-Methylcytosine; Animals; Antimutagenic Agents; Apurinic Acid; Cytosine; DNA Repair; DNA Replicatio

1993
DNA methylation and cancer.
    EXS, 1993, Volume: 64

    Topics: 5-Methylcytosine; Animals; Cytosine; Dinucleoside Phosphates; DNA; DNA Repair; Genes, p53; Genes, Tu

1993
The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene.
    British journal of cancer, 1996, Volume: 73, Issue:3

    Topics: 5-Methylcytosine; Cytosine; DNA, Neoplasm; Genes, p53; Humans; Mutation; Neoplasms; Tumor Suppressor

1996
DNA methylation and polyamines in embryonic development and cancer.
    The International journal of developmental biology, 1995, Volume: 39, Issue:5

    Topics: 5-Methylcytosine; Animals; Cell Transformation, Neoplastic; Cytosine; DNA; DNA (Cytosine-5-)-Methylt

1995
DNA methylation errors and cancer.
    Cancer research, 1996, Jun-01, Volume: 56, Issue:11

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans;

1996
Mechanisms of spontaneous human cancers.
    Environmental health perspectives, 1996, Volume: 104 Suppl 3

    Topics: 5-Methylcytosine; CpG Islands; Cytosine; Disease Susceptibility; DNA Damage; Environmental Exposure;

1996
The relationship of DNA methylation to cancer.
    Cancer surveys, 1996, Volume: 28

    Topics: 5-Methylcytosine; Azacitidine; CpG Islands; Cytosine; Decitabine; DNA Methylation; Enzyme Inhibitors

1996
Experimental manipulation of genomic methylation.
    Seminars in cancer biology, 1996, Volume: 7, Issue:5

    Topics: Animals; Cytosine; DNA; DNA Methylation; DNA, Neoplasm; Genome; Humans; Mice; Neoplasms; Neoplasms,

1996
Mutagenic and epigenetic effects of DNA methylation.
    Mutation research, 1997, Volume: 386, Issue:2

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; Enzymes; Gene Expression Regulation, Neoplasti

1997
Altered DNA methylation and genome instability: a new pathway to cancer?
    Proceedings of the National Academy of Sciences of the United States of America, 1997, Mar-18, Volume: 94, Issue:6

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA, Neoplasm; Genes, Tumor Suppressor; Humans

1997
DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis.
    Mutation research, 1997, Apr-14, Volume: 375, Issue:1

    Topics: 5-Methylcytosine; Alkylating Agents; Animals; Cytosine; DNA Damage; DNA Methylation; DNA Modificatio

1997
Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis.
    Carcinogenesis, 1997, Volume: 18, Issue:5

    Topics: 5-Methylcytosine; Alleles; Animals; Cell Differentiation; Chromatin; CpG Islands; Cytosine; DNA Meth

1997
Oncogenic mechanisms mediated by DNA methylation.
    Molecular medicine today, 1997, Volume: 3, Issue:5

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA; DNA Methylation; Humans; Mammals; Mutation; Neoplasms; Nuc

1997
Cytosine methylation and the ecology of intragenomic parasites.
    Trends in genetics : TIG, 1997, Volume: 13, Issue:8

    Topics: Animals; Cytosine; DNA Methylation; DNA Transposable Elements; Gametogenesis; Gene Expression Regula

1997
Mutagenesis in the P53 gene.
    Biochimica et biophysica acta, 1997, Aug-08, Volume: 1333, Issue:1

    Topics: 5-Methylcytosine; Carcinogens, Environmental; Cytosine; DNA Damage; Genes, p53; Humans; Mutagens; Mu

1997
Dynamic interrelationships between DNA replication, methylation, and repair.
    American journal of human genetics, 1997, Volume: 61, Issue:6

    Topics: 5-Methylcytosine; Animals; Chromatin; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; C

1997
Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations?
    Environmental and molecular mutagenesis, 1998, Volume: 31, Issue:3

    Topics: 5-Methylcytosine; Animals; Benzo(a)pyrene; Breast Neoplasms; Carcinogens, Environmental; Colonic Neo

1998
Cytosine methylation and human cancer.
    Current opinion in oncology, 2000, Volume: 12, Issue:1

    Topics: Cell Transformation, Neoplastic; Cytosine; DNA Methylation; Humans; Neoplasms

2000
DNA methylation: past, present and future directions.
    Carcinogenesis, 2000, Volume: 21, Issue:3

    Topics: 5-Methylcytosine; Antimetabolites, Antineoplastic; Azacitidine; Carcinogens; Chromatin; Cytosine; DN

2000
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
    Annals of internal medicine, 2001, Apr-03, Volume: 134, Issue:7

    Topics: 5-Methylcytosine; Acetylation; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Tr

2001
Methylation matters.
    Journal of medical genetics, 2001, Volume: 38, Issue:5

    Topics: 5-Methylcytosine; Chromosome Aberrations; CpG Islands; Cytosine; DNA Methylation; DNA Transposable E

2001
Methylation, mutation and cancer.
    BioEssays : news and reviews in molecular, cellular and developmental biology, 1992, Volume: 14, Issue:1

    Topics: 5-Methylcytosine; Animals; Cell Transformation, Neoplastic; Cytosine; Deamination; DNA; DNA, Neoplas

1992
5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene.
    Princess Takamatsu symposia, 1991, Volume: 22

    Topics: 5-Methylcytosine; Animals; Cytosine; DNA; Genes, p53; Humans; Mutagens; Mutation; Neoplasms

1991
Hypomethylation of DNA in the regulation of gene expression.
    Developmental biology (New York, N.Y. : 1985), 1988, Volume: 5

    Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Differentiation; Cytosine; DNA; Gene Expression Regulat

1988

Trials

7 trials available for cytosine and Neoplasms

ArticleYear
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-R

2009
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
    Investigational new drugs, 2006, Volume: 24, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cyt

2006
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1

    Topics: Antineoplastic Agents; Body Fluid Compartments; Cytosine; Dioxolanes; Dose-Response Relationship, Dr

2006
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2

    Topics: Adult; Aged; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; D

2008
[Bropirimine (U-54461S) phase I clinical studies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:14

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cytosine; Drug Administration Schedule; Fe

1996
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-01, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relations

2002
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-15, Volume: 20, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxol

2002

Other Studies

89 other studies available for cytosine and Neoplasms

ArticleYear
Photoreactive Cytosine-Functionalized Self-Assembled Micelles with Enhanced Cellular Uptake Capability for Efficient Cancer Chemotherapy.
    Biomacromolecules, 2021, 12-13, Volume: 22, Issue:12

    Topics: Cytosine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Micelles; Neoplasms

2021
Blood DNA methylation signatures are associated with social determinants of health among survivors of childhood cancer.
    Epigenetics, 2022, Volume: 17, Issue:11

    Topics: Cancer Survivors; Child; CpG Islands; Cytosine; DNA Methylation; Epigenesis, Genetic; Genome-Wide As

2022
Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect.
    Oncoimmunology, 2022, Volume: 11, Issue:1

    Topics: Animals; CD8-Positive T-Lymphocytes; Cytosine; Guanine; Interferon-gamma; Killer Cells, Natural; Lym

2022
Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A.
    European journal of medicinal chemistry, 2022, Nov-15, Volume: 242

    Topics: Animals; Cytosine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase

2022
Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy.
    Acta biomaterialia, 2022, 10-15, Volume: 152

    Topics: Adjuvants, Immunologic; Cell Line, Tumor; Cytosine; Cytostatic Agents; Doxorubicin; Guanosine; Human

2022
A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
    Biomaterials, 2022, Volume: 289

    Topics: Animals; Antigens, Neoplasm; Cancer Vaccines; Cytosine; Guanine; Humans; Immune Checkpoint Inhibitor

2022
The gene variant for desmin rs1058261 may protect against combined cancer and cardiovascular death, the Tampere adult population cardiovascular risk study.
    Medicine, 2022, Oct-07, Volume: 101, Issue:40

    Topics: Adult; Cardiovascular Diseases; Cytosine; Desmin; Genotype; Heart Disease Risk Factors; Humans; Neop

2022
Determinants of DNMT2/TRDMT1 preference for substrates tRNA and DNA during the evolution.
    RNA biology, 2023, Volume: 20, Issue:1

    Topics: Animals; Cytosine; DNA; DNA (Cytosine-5-)-Methyltransferases; Humans; Mammals; Methyltransferases; N

2023
m
    Nature communications, 2020, 06-05, Volume: 11, Issue:1

    Topics: Animals; Cell Line, Tumor; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DNA Breaks, Double-Strand

2020
Methylation and demethylation of DNA and histones in chromatin: the most complicated epigenetic marker.
    Experimental & molecular medicine, 2017, 04-28, Volume: 49, Issue:4

    Topics: Animals; Chromatin; Cytosine; DNA Demethylation; DNA Methylation; Epigenesis, Genetic; Genetic Marke

2017
TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents.
    Epigenetics, 2017, Volume: 12, Issue:10

    Topics: Cyclin B1; Cytosine; DNA Damage; DNA Methylation; DNA Repair; DNA-Activated Protein Kinase; Gene Exp

2017
5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages.
    Cell research, 2017, Volume: 27, Issue:10

    Topics: 5-Methylcytosine; Adult; Aged; Animals; Cell-Free Nucleic Acids; Circulating Tumor DNA; Cytosine; DN

2017
A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy.
    Nanoscale, 2017, Sep-28, Volume: 9, Issue:37

    Topics: Cytosine; Doxorubicin; Guanine; Humans; Immunotherapy; Metal Nanoparticles; Nanoconjugates; Neoplasm

2017
Global delay in nascent strand DNA methylation.
    Nature structural & molecular biology, 2018, Volume: 25, Issue:4

    Topics: Cell Cycle; Cell Proliferation; CpG Islands; Cytosine; DNA; DNA (Cytosine-5-)-Methyltransferases; DN

2018
A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils.
    Molecular and cellular biology, 2019, 01-01, Volume: 39, Issue:1

    Topics: Carcinogens; Cell Line; Cell Transformation, Neoplastic; Cytidine Deaminase; Cytosine; DNA, Single-S

2019
Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
    Scientific reports, 2019, 06-05, Volume: 9, Issue:1

    Topics: Catalytic Domain; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Cytidine Deaminase; Cytopl

2019
Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease.
    Cell cycle (Georgetown, Tex.), 2013, Jun-15, Volume: 12, Issue:12

    Topics: 5-Methylcytosine; Cell Differentiation; Cell Line, Tumor; Cytosine; DNA Methylation; Epigenomics; Fe

2013
PAPD5-mediated 3' adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Aug-05, Volume: 111, Issue:31

    Topics: Adenine; Base Sequence; Cytosine; Exoribonucleases; Gene Expression Profiling; Gene Expression Regul

2014
Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A.
    Molecular cell, 2014, Aug-21, Volume: 55, Issue:4

    Topics: 5-Methylcytosine; Basic Helix-Loop-Helix Transcription Factors; Cell Cycle Proteins; Cell Line, Tumo

2014
Decrease of 5-hydroxymethylcytosine in rat liver with subchronic exposure to genotoxic carcinogens riddelliine and aristolochic acid.
    Molecular carcinogenesis, 2015, Volume: 54, Issue:11

    Topics: 5-Methylcytosine; Animals; Aristolochic Acids; Carcinogenesis; Carcinogens; Cytosine; DNA-Binding Pr

2015
Uncovering the polymerase-induced cytotoxicity of an oxidized nucleotide.
    Nature, 2015, Jan-29, Volume: 517, Issue:7536

    Topics: Adenine; Base Pairing; Catalytic Domain; Crystallography, X-Ray; Cytosine; Cytotoxins; Deoxyguanine

2015
Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer patients by an enzyme-based immunoassay.
    Analytica chimica acta, 2014, Dec-10, Volume: 852

    Topics: 5-Methylcytosine; Cytosine; DNA; Epigenesis, Genetic; Humans; Immunoenzyme Techniques; Limit of Dete

2014
CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer.
    Nature, 2015, Aug-06, Volume: 524, Issue:7563

    Topics: 5-Methylcytosine; Animals; Cell Death; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Cytosine; Deo

2015
Molecular biology: Salvaging the genome.
    Nature, 2015, Aug-06, Volume: 524, Issue:7563

    Topics: Animals; Cytidine; Cytidine Deaminase; Cytosine; Epigenesis, Genetic; Humans; Neoplasms

2015
Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Aug-18, Volume: 112, Issue:33

    Topics: Biomarkers, Tumor; Carcinogenesis; Chromatography, High Pressure Liquid; Cytosine; DNA Mutational An

2015
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy.
    Cancer discovery, 2016, Volume: 6, Issue:1

    Topics: 5-Methylcytosine; Alternative Splicing; Animals; Cell Line, Tumor; Cytosine; Epigenesis, Genetic; Ge

2016
APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
    Genome research, 2016, Volume: 26, Issue:2

    Topics: Cytidine Deaminase; Cytosine; DNA Methylation; DNA Mutational Analysis; DNA Replication; Exome; Huma

2016
3-methylcytosine in cancer: an underappreciated methyl lesion?
    Epigenomics, 2016, Volume: 8, Issue:4

    Topics: Biomarkers, Tumor; Cytosine; DNA Damage; DNA Methylation; DNA Repair; Humans; Neoplasms

2016
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
    Antiviral research, 2016, Volume: 134

    Topics: Aged; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytos

2016
Incorporation of 5-chlorocytosine into mammalian DNA results in heritable gene silencing and altered cytosine methylation patterns.
    Carcinogenesis, 2009, Volume: 30, Issue:5

    Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Cytosine; DNA; DNA Damage; DNA Replication; Gene Silenci

2009
Label-free analysis of DNA methylation using optofluidic ring resonators.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2009, Volume: 2009

    Topics: Animals; Cell Proliferation; Cytosine; DNA Methylation; Epigenesis, Genetic; Equipment Design; Human

2009
Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.
    The journal of gene medicine, 2010, Volume: 12, Issue:5

    Topics: Adenoviridae Infections; Adenoviruses, Human; Animals; Biological Transport; Cell Death; Cell Line;

2010
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytos

2011
Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells.
    Experimental cell research, 2010, Nov-15, Volume: 316, Issue:19

    Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Nucleus; Cytidine; Cytosine; DNA Methylat

2010
Computational studies on effects of MDMA as an anticancer drug on DNA.
    Chemical biology & drug design, 2010, Volume: 76, Issue:5

    Topics: Adenine; Antineoplastic Agents; Base Pairing; Cytosine; DNA; Drug Design; Guanine; Humans; Intercala

2010
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
    British journal of cancer, 2010, Oct-26, Volume: 103, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Death; Cell Line,

2010
Conservation and divergence of DNA methylation in eukaryotes: new insights from single base-resolution DNA methylomes.
    Epigenetics, 2011, Volume: 6, Issue:2

    Topics: Animals; CpG Islands; Cytosine; DNA Methylation; Embryonic Stem Cells; Epigenomics; Eukaryota; Evolu

2011
Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization.
    Bioinformatics (Oxford, England), 2011, Jan-15, Volume: 27, Issue:2

    Topics: Algorithms; Base Composition; Cell Line, Tumor; Cytosine; DNA Copy Number Variations; Genomics; Guan

2011
Structural basis for the inhibition of human alkyladenine DNA glycosylase (AAG) by 3,N4-ethenocytosine-containing DNA.
    The Journal of biological chemistry, 2011, Apr-15, Volume: 286, Issue:15

    Topics: Catalytic Domain; Cytosine; DNA Damage; DNA Glycosylases; DNA, Neoplasm; Humans; Hydrogen Bonding; N

2011
Quantum-chemical study of interactions of trans-resveratrol with guanine-thymine dinucleotide and DNA-nucleobases.
    Journal of molecular modeling, 2011, Volume: 17, Issue:12

    Topics: Adenine; Antineoplastic Agents, Phytogenic; Cytosine; DNA; DNA Breaks; Guanine; Humans; Hydrogen Bon

2011
Effect of CpG methylation on DNA binding protein: molecular dynamics simulations of the homeodomain PITX2 bound to the methylated DNA.
    Journal of molecular graphics & modelling, 2011, Volume: 29, Issue:7

    Topics: Amino Acid Sequence; Binding Sites; CpG Islands; Cytosine; DNA; DNA Methylation; DNA-Binding Protein

2011
Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2012, Volume: 269, Issue:2

    Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Cidofovir; Cytosine; Injections, Intrales

2012
5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.
    Cancer research, 2011, Dec-15, Volume: 71, Issue:24

    Topics: 5-Methylcytosine; Animals; Base Sequence; Brain; Brain Neoplasms; Carcinoma, Squamous Cell; Cell Lin

2011
Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation.
    Cancer science, 2012, Volume: 103, Issue:4

    Topics: 5-Methylcytosine; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms; Cytosine;

2012
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.
    Oncogene, 2013, Jan-31, Volume: 32, Issue:5

    Topics: 5-Methylcytosine; Animals; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cytosine; Dioxygenase

2013
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine;

2012
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.
    Cancer research, 2002, Aug-01, Volume: 62, Issue:15

    Topics: 5-Methylcytosine; 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Adenocarcinoma; Breast

2002
Cellular vitamins, DNA methylation and cancer risk.
    The Journal of nutrition, 2002, Volume: 132, Issue:8 Suppl

    Topics: 5-Methylcytosine; Cytosine; DNA Methylation; Humans; Immunohistochemistry; Neoplasms; Risk Factors;

2002
Troxacitabine (Shire Pharmaceuticals).
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:10

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Humans; Neoplasms; S

2002
A systematic profile of DNA methylation in human cancer cell lines.
    Cancer research, 2003, Mar-01, Volume: 63, Issue:5

    Topics: 5-Methylcytosine; Azacitidine; Cluster Analysis; CpG Islands; Cytosine; Decitabine; DNA Methylation;

2003
Troxacitabine: BCH 4556, SPD 758, Troxatyl.
    Drugs in R&D, 2003, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Drug Industry; Humans; Infusi

2003
Integrin beta3 Leu33Pro homozygosity and risk of cancer.
    Journal of the National Cancer Institute, 2003, Aug-06, Volume: 95, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Animals; Cytosine; Denmark; Disease Progression; Female; Ge

2003
The formation of cytidine nucleotides and RNA cytosine from orotic acid by the Novikoff tumor in vitro.
    Cancer research, 1959, Volume: 19, Issue:6, Part 1

    Topics: Cytidine; Cytosine; In Vitro Techniques; Neoplasms; Nucleosides; Nucleotides; Orotic Acid; Pyrimidin

1959
FRACTIONS WITH DIFFERING BASE COMPOSITION IN RNA FROM MALIGNANT CELLS OF MOUSE.
    Journal of molecular biology, 1963, Volume: 7

    Topics: Adenine; Animals; Autoradiography; Base Composition; Cytosine; Electrophoresis; Guanine; Mice; Neopl

1963
[EFFECT OF SOME PYRIMIDINE DERIVATIVES ON THE TOXIC AND ANTINEOPLASTIC ACTION OF SARCOLYSINE].
    Voprosy onkologii, 1963, Volume: 9

    Topics: Antineoplastic Agents; Cytosine; Erythrocyte Count; Leukocyte Count; Melphalan; Neoplasm Metastasis;

1963
[EFFECT OF SOME PYRIMIDINE DERIVATIVES ON THE GROWTH OF CROCKER'S SARCOMA].
    Voprosy onkologii, 1963, Volume: 9

    Topics: Animals; Antineoplastic Agents; Cytosine; Mice; Neoplasms; Pharmacology; Pyrimidines; Research; Sarc

1963
[ON THE EFFECT OF CERTAIN PYRIMIDINE DERIVATIVES ON THE METASTASIZATION OF TRANSPLANTABLE SSK RAT SARCOMA].
    Voprosy onkologii, 1964, Volume: 10

    Topics: Cytosine; Neoplasm Metastasis; Neoplasms; Pharmacology; Pyrimidines; Rats; Research; Sarcoma; Sarcom

1964
SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN.
    Biochemical pharmacology, 1964, Volume: 13

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Body Weight; Cytarabine; Cytosine; Leukemia;

1964
THE REVERSAL OF CYTOSINE ARABINOSIDE ACTIVITY IN VIVO BY DEOXYCYTIDINE.
    Biochemical pharmacology, 1964, Volume: 13

    Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cytarabine; Cytosine; Deoxycytidine; Leuke

1964
THE EFFECT OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE HYDROCHLORIDE ON MURINE NEOPLASMS.
    Cancer research, 1964, Volume: 24

    Topics: Animals; Anti-Bacterial Agents; Antibodies; Antineoplastic Agents; Blood Cells; Carcinoma, Ehrlich T

1964
TUMOR AND VIRUS ANTIGENS OF SIMIAN VIRUS 40: DIFFERENTIAL INHIBITION OF SYNTHESIS BY CYTOSINE ARABINOSIDE.
    Science (New York, N.Y.), 1965, Feb-05, Volume: 147, Issue:3658

    Topics: Antigens; Antigens, Viral; Cytarabine; Cytosine; Humans; Idoxuridine; Metabolism; Neoplasms; Nucleos

1965
SPECIFICITY OF DNA FROM NEOPLASTIC TISSUES IN VIVO AND IN VITRO.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Adenine; Animals; Carbon Isotopes; Cytosine; DNA; DNA, Neoplasm; Formates; Guanine; Histocytochemist

1964
ON THE OXIDATIVE PHOSPHORYLATION AND NUCLEIC ACIDS METABOLISM IN SOME ORGANS OF ANIMALS WITH TRANSPLANTABLE TUMOURS.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Adenine; Carbohydrate Metabolism; Cytosine; DNA; DNA, Neoplasm; Glycolysis; Guanine; Intestines; Kid

1964
COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE.
    Biochemical pharmacology, 1965, Volume: 14

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Chromatography; Cytarabine; Cytosine; DNA; DNA, Neopl

1965
BASE COMPOSITION OF HIGH MOLECULAR WEIGHT NUCLEAR RNA OF WALKER TUMOR AND LIVER OF THE RAT.
    Cancer research, 1965, Volume: 25

    Topics: Adenine; Adenine Nucleotides; Animals; Base Composition; Carcinoma 256, Walker; Cytosine; Cytosine N

1965
Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Cy

2004
Determination of 5-methyl-cytosine and cytosine in tumor DNA of cancer patients.
    Electrophoresis, 2005, Volume: 26, Issue:6

    Topics: 5-Methylcytosine; Cytosine; DNA Methylation; DNA, Neoplasm; Electrophoresis, Capillary; Humans; Neop

2005
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Methods in molecular medicine, 2005, Volume: 111

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms;

2005
Cidofovir and the black box warning.
    The Annals of otology, rhinology, and laryngology, 2005, Volume: 114, Issue:11

    Topics: Animals; Antineoplastic Agents; Cidofovir; Cytosine; Disease Progression; Drug Labeling; Humans; Lar

2005
G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Oligonucleotides, 2006,Spring, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; B-Lymphocytes; Carcinoma; Ce

2006
DNA cytosine methylation profile in various cancer-related genes is altered in cultured rat hepatocyte cell lines as compared with primary hepatocytes.
    Oncology reports, 2006, Volume: 15, Issue:5

    Topics: Animals; Cell Culture Techniques; Cells, Cultured; CpG Islands; Cytosine; DNA Methylation; Genes, Ne

2006
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
    British journal of cancer, 2007, Sep-03, Volume: 97, Issue:5

    Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor;

2007
The 5-methylcytosine content of DNA from human tumors.
    Nucleic acids research, 1983, Oct-11, Volume: 11, Issue:19

    Topics: 5-Methylcytosine; Brain Chemistry; Cytosine; DNA; DNA Restriction Enzymes; DNA, Neoplasm; Female; Hu

1983
Extent of DNA methylation in human tumor cells.
    Journal of the National Cancer Institute, 1983, Volume: 71, Issue:4

    Topics: 5-Methylcytosine; Base Composition; Cell Line; Chromatography, High Pressure Liquid; Cytosine; DNA;

1983
Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants.
    Cancer research, 1983, Volume: 43, Issue:10

    Topics: 5-Methylcytosine; Autoradiography; Cell Line; Cerebellar Neoplasms; Cytosine; DNA; Fibroblasts; Huma

1983
A cytosine methyltransferase converts 5-methylcytosine in DNA to thymine.
    Biochemistry, 1995, Nov-14, Volume: 34, Issue:45

    Topics: 5-Methylcytosine; Cytosine; DNA; DNA-Cytosine Methylases; Escherichia coli; Humans; Methylation; Mol

1995
Methylation and p16: suppressing the suppressor.
    Nature medicine, 1995, Volume: 1, Issue:7

    Topics: 5-Methylcytosine; Carrier Proteins; Cell Transformation, Neoplastic; Cocarcinogenesis; CpG Islands;

1995
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
    Nature medicine, 1995, Volume: 1, Issue:7

    Topics: 5-Methylcytosine; Alleles; Azacitidine; Base Sequence; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu

1995
Hypomethylation of DNA: a possible nongenotoxic mechanism underlying the role of cell proliferation in carcinogenesis.
    Environmental health perspectives, 1993, Volume: 101 Suppl 5

    Topics: 5-Methylcytosine; Animals; Cell Division; Cytosine; DNA; Female; Liver Neoplasms, Experimental; Male

1993
Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots.
    Cancer research, 1998, May-15, Volume: 58, Issue:10

    Topics: Acetoxyacetylaminofluorene; Aflatoxin B1; Binding Sites; Carcinogens; CpG Islands; Cytosine; DNA Met

1998
DNA methylation influences the decatenation activity of topoisomerase II.
    International journal of biological macromolecules, 2001, Jan-10, Volume: 28, Issue:2

    Topics: Animals; CpG Islands; Crithidia fasciculata; Cytosine; DNA Methylation; DNA Topoisomerases, Type II;

2001
Chromosome-wide assessment of replication timing for human chromosomes 11q and 21q: disease-related genes in timing-switch regions.
    Human molecular genetics, 2002, Jan-01, Volume: 11, Issue:1

    Topics: Alzheimer Disease; Chromosome Mapping; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 21; Cyt

2002
High-resolution liquid chromatographic analysis of methylated purine and pyrimidine bases in transfer RNA.
    Journal of chromatography, 1976, Jan-07, Volume: 116, Issue:1

    Topics: Adenine; Animals; Cattle; Chemical Phenomena; Chemistry; Chromatography, Liquid; Cytosine; Guanine;

1976
Childhood cancer: the improving prognosis.
    Postgraduate medicine, 1976, Volume: 59, Issue:2

    Topics: Asparaginase; Child; Cyclophosphamide; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combinatio

1976
The cell cycle and cancer chemotherapy.
    The American journal of nursing, 1978, Volume: 78, Issue:7

    Topics: Antineoplastic Agents; Cell Cycle; Cyclophosphamide; Cytosine; DNA Replication; Dose-Response Relati

1978
Phase I study of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer, in cancer patients.
    Journal of biological response modifiers, 1986, Volume: 5, Issue:4

    Topics: Adult; Aged; Cytosine; Drug Evaluation; Humans; Interferon Inducers; Interferons; Male; Melanoma; Mi

1986
Bropirimine.
    Cancer investigation, 1989, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Cytosine; Drug Evaluation; Humans; Neoplasms

1989
Patterns of DNA methylation and gene expression in human tumor cell lines.
    Cancer research, 1986, Volume: 46, Issue:6

    Topics: Cell Line; Collagen; Cytosine; DNA, Neoplasm; Gene Expression Regulation; Humans; Methylation; Neopl

1986
Flexibility of nucleic acid bases and its possible relationship with carcinogenesis.
    Progress in clinical and biological research, 1985, Volume: 172B

    Topics: Adenine; Animals; Cytosine; DNA; Guanine; Humans; Hydrogen Bonding; Neoplasms; Nucleic Acid Conforma

1985